Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 19/20 | 0.72 |
| ▸ | GSK3B | P49841 | 19/20 | 0.72 |
| ▸ | GSK3A | P49840 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16711049 | 0.98 | MAPT (0.72) | MAPTGSK3BGSK3A | |
| SCHEMBL16702800 | 0.95 | GSK3B (0.76) | MAPTGSK3BGSK3A | |
| SCHEMBL18125249 | 0.84 | GSK3B (0.91) | MAPTGSK3BGSK3A | |
| SCHEMBL16703950 | 0.84 | GSK3B (1.00) | MAPTGSK3BGSK3A | |
| SCHEMBL16704119 | 0.83 | GSK3B (0.96) | MAPTGSK3BGSK3A | |
| SCHEMBL16703119 | 0.82 | GSK3B (0.76) | MAPTGSK3BGSK3A | |
| SCHEMBL18125247 | 0.82 | GSK3B (0.91) | MAPTGSK3BGSK3A | |
| SCHEMBL18107505 | 0.82 | GSK3B (1.00) | MAPTGSK3BGSK3A | |
| SCHEMBL16704211 | 0.82 | GSK3B (0.78) | MAPTGSK3BGSK3A | |
| SCHEMBL16704116 | 0.82 | MAPT (1.00) | MAPTGSK3BGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3066092-B1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-05 | — | — | EP | disclosed |
| EP-3066093-B9 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-02-07 | — | — | EP | disclosed |
| US-9809573-B2 | Substituted pyridine derivatives useful as GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809573-B2 | Substituted pyridine derivatives useful as GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809573-B2 | Substituted pyridine derivatives useful as GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-07 | — | — | US | disclosed |
| EP-3066093-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-04 | — | — | EP | disclosed |
| US-9718804-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160289210-A1 | Substituted Pyridine Derivatives Useful as GSK-3 Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160289210-A1 | Substituted Pyridine Derivatives Useful as GSK-3 Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160289210-A1 | Substituted Pyridine Derivatives Useful as GSK-3 Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160272621-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-22 | — | — | US | disclosed |
| EP-3066092-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS GSK-3 INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-3066093-A1 | GSK-3 INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015069593-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015069593-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015069594-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289210-A1 | Substituted Pyridine Derivatives Useful as GSK-3 Inhibitors | GSK3B, GSK3A, GRIN3A | MAPT 402/4885GSK3B 1/4885GSK3A 2/4885 |
| US-20160272621-A1 | GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | MAPT 90/4885GSK3B 1/4885GSK3A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.